Inotuzumab Ozogamicin 和一线化疗治疗年轻成人新诊断 B 型急性淋巴细胞白血病
评估将 Inotuzumab Ozogamicin(一种结合的抗 CD22 单克隆抗体)加入新诊断前体 B 细胞 ALL 的年轻人(18-39 岁)一线治疗的疗效的 III 期试验
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as [intervention], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.
研究概览
地位
地位
干预/治疗
干预/治疗
- 其他:Laboratory Biomarker Analysis
- 药品:Cyclophosphamide
- 药品:Doxorubicin
- 生物:Rituximab
- 药品:Vincristine Sulfate
- 药品:Daunorubicin Hydrochloride
- 药品:Mercaptopurine
- 生物:Inotuzumab Ozogamicin
- 药品:Dexamethasone
- 药品:Thioguanine
- 药品:Allopurinol
- 药品:Cytarabine
- 药品:Pegylated L-Asparaginase
- 药品:Methotrexate
- 程序:Bone Marrow Aspiration and Biopsy
详细说明
PRIMARY OBJECTIVES:
I. To confirm tolerability of the combination regimen with the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III) III. To determine the safety and tolerability of a reduced dose of inotuzumab ozogamicin and two cycles of blinatumomab added to the pediatric-inspired regimen of CALGB 10403 (Pilor cohort).
SECONDARY OBJECTIVES:
I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall survival (OS) in patients who achieve an induction response.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, with censoring for transplant.
III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and correlate this with the EFS, DFS and OS.
IV. To determine the prognosis based on patients' low-density array (LDA) gene signature in terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to the C10403 backbone regimen.
V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of CALGB 10403.
CORRELATIVE SCIENCE OBJECTIVES:
I. To assess both the correlation of MRD post-induction and at sequential timepoints with LDA signature.
II. To evaluate the influence of MRD status (detectable vs. not and as a continuous measure) in relation to EFS both in the univariate setting as well as adjusting for other clinical features including initial white blood cell (WBC), ethnicity, sex and age at diagnosis.
III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD during treatment with inotuzumab in patients randomized to the experimental treatment arm.
IV. To perform genomic analyses to identify and evaluate the incidence and clinical significance of recurring novel fusion genes including those associated with the BCR-ABL1-like signature and to correlate with MRD status, CR rate, EFS and OS.
V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent and young adult (AYA) population.
VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT, NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association study [GWAS]), are correlated with increased rates of target toxicities including peripheral neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and osteonecrosis, and correlate with treatment discontinuation and other clinical response parameters including complete response (CR) rate, EFS, and OS.
VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and investigate its correlation with toxicities and treatment outcomes.
VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.
IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of adherence.
X. To determine the impact of adherence on risk of relapse among AYAs with ALL. XI. To correlate specific karyotype groups (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters.
XII. To correlate specific karyotype groups with response rates, response duration, survival, and cure in patients treated on this protocol.
XIII. To correlate specific karyotype groups with MRD. XIV. To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse.
XV. To define the rate, analytical performance, and diagnostic yield of ChromoSeq vs. conventional G-banded karyotyping and fluorescence in situ hybridization (FISH) for B ALL patients in a multicenter setting.
OUTLINE:
COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once daily until peripheral blasts and extramedullary disease are reduced and cytarabine intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride intravenously, over 1 to 30 minutes (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV twice daily (BID) on days 1-7 and 15-21, pegaspargase for patients >21.5 years IV, over 1 to 2 hours on day 4, 5, or 6, or calaspargase pegol IV, over 1 hour, on days 4, 5 or 6 and methotrexate IT over 1 minute on days 8 and 29. Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.
Patients enrolled prior to Update 8 with response to remission induction therapy are randomized to 1 of 2 arms. Patients enrolled after amendment 8 are assigned to the pilot cohort. Patients with no response are omitted from the study.
ARM I (CLOSED 7/23/2025):
COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV, over 1 to 10 minutes on days 15, 22, 43, and 50. Patients >21.5 years also receive pegaspargase IV, over 1 to 2 hours, on days 15 and 43 and patients <21.5 years old receive calaspargase pegol IV, over 1 hour, on days 2 and 22, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36. Patients with evidence of testicular disease at diagnosis also receive radiation therapy (RT). Patients who are MRD+ and CD19+ after completion of this course receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 56.
COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 11, 21, 31, and 41, methotrexate IV, over 24 hours, and IT on days 1, 11, 21, 31, and 41, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.
COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV, over 3 to 60 minutes, on days 1, 8, and 15, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, on day 4, 5, or 6 and day 43, patients <21.5 years old receive calaspargase pegol IV, over 1 hour, on days 2 and 22. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy one week after completion of course IV.
COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.
Patients undergo multigated acquisition scan (MUGA) or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.
ARM II (CLOSED 7/23/2025): Patients receive inotuzumab ozogamicin IV, over 1 hour, on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who are MRD+ and CD19+ after completion of 2 cycles of inotuzumab ozogamicin receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.
PILOT COHORT: Patients receive inotuzumab ozogamicin IV, over 1 hour, on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28.
COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV, over 1 to 10 minutes, on days 15, 22, 43, and 50. Patients > 21.5 years old also receive pegaspargase IV, over 1 to 2 hours, on days 15 and 43 and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour, on days 15 and 43, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20+ patients receive rituximab IV on days 1, 8, 29, and 36. Patients with evidence of testicular disease at diagnosis also receive RT. Patients then undergo bone marrow aspirate and biopsy on day 56.
BLINATUMOMAB: Patients receive blinatumomab IV, continuously, on days 1-28 of one 42-day cycle in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO or IV prior to starting the blinatumomab cycle, and a single dose of methotrexate IT between cycle days 29 and 42.
COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 11, 21, 31, and 41, methotrexate IV, over 24 hours, and IT on days 1, 11, 21, 31, and 41, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.
BLINATUMOMAB: Patients receive blinatumomab IV, continuously, on days 1-28 of one 42-day cycle in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO or IV prior to starting the blinatumomab cycle, and a single dose of methotrexate IT between cycle days 29 and 42. Patients who are MRD positive and CD19+ after Course II may continue to receive blinatumomab IV, continuously on days 1-28 of each cycle. Cycles repeat every 42 days for an additional 2 cycles in the absence of disease progression or unacceptable toxicity, per investigator discretion.
COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV, over 1 to 10 minutes on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV, over 3 to 60 minutes, on days 1, 8, and 15, patients > 21.5 years old receive pegaspargase IV, over 1 to 2 hours, on day 4, 5, or 6 and day 43, patients < 21.5 years old receive calaspargase pegol IV, over 1 hour, on day 4, 5, or 6 and 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy one week after completion of course IV.
COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT on day 1 of cycles 1-4 and PO once weekly (QW) of each cycle. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.
Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.
After completion of study treatment, patients are followed up every 2 months for 2 years, every 3 months 2 years, and then every 6 months for up to 10 years.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Daniel J. DeAngelo, MD, PhD
- 电话号码:617-632-2645
- 邮箱:daniel_deangelo@dfci.harvard.edu
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 5G2
- 暂停
- Arthur J E Child Comprehensive Cancer Centre
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- 暂停
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 2Y9
- 招聘中
- QEII Health Sciences Centre/Nova Scotia Health Authority
-
接触:
- Site Public Contact
- 电话号码:902-473-6000
-
首席研究员:
- Nicholas A. Forward
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L6
- 招聘中
- Ottawa Hospital and Cancer Center-General Campus
-
接触:
- Site Public Contact
- 电话号码:613-761-4395
-
首席研究员:
- Jill Fulcher
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- 暂停
- Jewish General Hospital
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 主动,不招人
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage、Alaska、美国、98508
- 暂停
- Anchorage Associates in Radiation Medicine
-
Anchorage、Alaska、美国、99504
- 暂停
- Anchorage Radiation Therapy Center
-
Anchorage、Alaska、美国、99508
- 暂停
- Alaska Breast Care and Surgery LLC
-
Anchorage、Alaska、美国、99508
- 暂停
- Alaska Oncology and Hematology LLC
-
Anchorage、Alaska、美国、99508
- 暂停
- Alaska Women's Cancer Care
-
Anchorage、Alaska、美国、99508
- 暂停
- Anchorage Oncology Centre
-
Anchorage、Alaska、美国、99508
- 暂停
- Katmai Oncology Group
-
Anchorage、Alaska、美国、99508
- 暂停
- Providence Alaska Medical Center
-
Fairbanks、Alaska、美国、99701
- 暂停
- Fairbanks Memorial Hospital
-
-
Arizona
-
Kingman、Arizona、美国、86401
- 暂停
- Kingman Regional Medical Center
-
Phoenix、Arizona、美国、85054
- 暂停
- Mayo Clinic Hospital in Arizona
-
Scottsdale、Arizona、美国、85259
- 撤销
- Mayo Clinic in Arizona
-
-
Arkansas
-
Fort Smith、Arkansas、美国、72903
- 暂停
- Mercy Hospital Fort Smith
-
-
California
-
Antioch、California、美国、94531
- 招聘中
- Kaiser Permanente-Deer Valley Medical Center
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Arroyo Grande、California、美国、93420
- 暂停
- PCR Oncology
-
Burbank、California、美国、91505
- 暂停
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Clovis、California、美国、93611
- 招聘中
- Community Cancer Institute
-
首席研究员:
- Mohammed S. Bukari
-
接触:
- Site Public Contact
- 电话号码:559-387-1827
-
Clovis、California、美国、93611
- 暂停
- University Oncology Associates
-
Costa Mesa、California、美国、92627
- 招聘中
- UC Irvine Health Cancer Center-Newport
-
首席研究员:
- Deepa Jeyakumar
-
接触:
- Site Public Contact
- 电话号码:877-827-8839
-
Dublin、California、美国、94568
- 招聘中
- Kaiser Permanente Dublin
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
-
首席研究员:
- Jennifer M. Suga
-
Fremont、California、美国、94538
- 招聘中
- Kaiser Permanente-Fremont
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Fresno、California、美国、93720
- 招聘中
- Kaiser Permanente-Fresno
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Fresno、California、美国、93720
- 暂停
- Fresno Cancer Center
-
Fresno、California、美国、93720
- 招聘中
- Kaiser Permanente Fresno Orchard Plaza
-
首席研究员:
- Jennifer M. Suga
-
接触:
- Site Public Contact
- 电话号码:833-574-2273
-
Irvine、California、美国、92612
- 招聘中
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
首席研究员:
- Deepa Jeyakumar
-
接触:
- Site Public Contact
- 电话号码:877-827-8839
- 邮箱:ucstudy@uci.edu
-
Modesto、California、美国、95356
- 招聘中
- Kaiser Permanente-Modesto
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Modesto、California、美国、95356
- 招聘中
- Kaiser Permanente- Modesto MOB II
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
-
首席研究员:
- Jennifer M. Suga
-
Oakland、California、美国、94611
- 招聘中
- Kaiser Permanente-Oakland
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Oakland、California、美国、94611
- 暂停
- Kaiser Permanente Oakland-Broadway
-
Orange、California、美国、92868
- 招聘中
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
首席研究员:
- Deepa Jeyakumar
-
接触:
- Site Public Contact
- 电话号码:877-827-8839
- 邮箱:ucstudy@uci.edu
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford Cancer Institute Palo Alto
-
首席研究员:
- Michaela Liedtke
-
接触:
- Site Public Contact
- 电话号码:650-498-7061
- 邮箱:cancertrialsinfo@stanford.edu
-
Rancho Cordova、California、美国、95670
- 暂停
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Redwood City、California、美国、94063
- 暂停
- Kaiser Permanente-Redwood City
-
Redwood City、California、美国、94063
- 暂停
- Kaiser Permanente- Marshall Medical Offices
-
Richmond、California、美国、94801
- 招聘中
- Kaiser Permanente-Richmond
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Rohnert Park、California、美国、94928
- 暂停
- Rohnert Park Cancer Center
-
Roseville、California、美国、95661
- 招聘中
- Kaiser Permanente-Roseville
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Roseville、California、美国、95678
- 暂停
- The Permanente Medical Group-Roseville Radiation Oncology
-
Sacramento、California、美国、95817
- 招聘中
- University of California Davis Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:916-734-3089
-
首席研究员:
- Brian A. Jonas
-
Sacramento、California、美国、95814
- 招聘中
- Kaiser Permanente Downtown Commons
-
首席研究员:
- Jennifer M. Suga
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:kpoct@kp.org
-
Sacramento、California、美国、95823
- 招聘中
- Kaiser Permanente-South Sacramento
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Sacramento、California、美国、95823
- 暂停
- South Sacramento Cancer Center
-
Sacramento、California、美国、95825
- 暂停
- Kaiser Permanente Sacramento Medical Center
-
San Francisco、California、美国、94115
- 招聘中
- Kaiser Permanente-San Francisco
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
San Jose、California、美国、95119
- 招聘中
- Kaiser Permanente-Santa Teresa-San Jose
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
San Leandro、California、美国、94577
- 招聘中
- Kaiser Permanente San Leandro
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
San Rafael、California、美国、94903
- 招聘中
- Kaiser San Rafael-Gallinas
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
San Rafael、California、美国、94903
- 暂停
- Kaiser Permanente-San Rafael
-
Santa Clara、California、美国、95051
- 招聘中
- Kaiser Permanente Medical Center - Santa Clara
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Santa Rosa、California、美国、95403
- 招聘中
- Kaiser Permanente-Santa Rosa
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
South San Francisco、California、美国、94080
- 暂停
- Kaiser Permanente Cancer Treatment Center
-
South San Francisco、California、美国、94080
- 招聘中
- Kaiser Permanente-South San Francisco
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Stockton、California、美国、95210
- 招聘中
- Kaiser Permanente-Stockton
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Vacaville、California、美国、95688
- 招聘中
- Kaiser Permanente Medical Center-Vacaville
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Vallejo、California、美国、94589
- 招聘中
- Kaiser Permanente-Vallejo
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
Walnut Creek、California、美国、94596
- 招聘中
- Kaiser Permanente-Walnut Creek
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Jennifer M. Suga
-
-
Colorado
-
Aurora、Colorado、美国、80012
- 暂停
- The Medical Center of Aurora
-
Aurora、Colorado、美国、80012
- 主动,不招人
- Rocky Mountain Cancer Centers-Aurora
-
Boulder、Colorado、美国、80303
- 主动,不招人
- Boulder Community Foothills Hospital
-
Boulder、Colorado、美国、80304
- 主动,不招人
- Rocky Mountain Cancer Centers-Boulder
-
Centennial、Colorado、美国、80112
- 主动,不招人
- Rocky Mountain Cancer Centers - Centennial
-
Denver、Colorado、美国、80220
- 暂停
- Rose Medical Center
-
Denver、Colorado、美国、80204
- 暂停
- Cancer Center of Colorado at Sloan's Lake
-
Denver、Colorado、美国、80206
- 暂停
- National Jewish Health-Main Campus
-
Denver、Colorado、美国、80218
- 主动,不招人
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver、Colorado、美国、80209
- 主动,不招人
- The Women's Imaging Center
-
Denver、Colorado、美国、80218
- 主动,不招人
- Colorado Blood Cancer Institute
-
Denver、Colorado、美国、80218
- 主动,不招人
- Rocky Mountain Cancer Centers-Midtown
-
Denver、Colorado、美国、80220
- 主动,不招人
- Rocky Mountain Cancer Centers-Rose
-
Denver、Colorado、美国、80220
- 主动,不招人
- Western Surgical Care
-
Denver、Colorado、美国、80218
- 暂停
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood、Colorado、美国、80113
- 暂停
- Swedish Medical Center
-
Englewood、Colorado、美国、80113
- 主动,不招人
- Mountain Blue Cancer Care Center - Swedish
-
Englewood、Colorado、美国、80113
- 主动,不招人
- Rocky Mountain Cancer Centers - Swedish
-
Englewood、Colorado、美国、80113
- 主动,不招人
- The Melanoma and Skin Cancer Institute
-
Golden、Colorado、美国、80401
- 暂停
- National Jewish Health-Western Hematology Oncology
-
Grand Junction、Colorado、美国、81501
- 暂停
- Saint Mary's Hospital and Regional Medical Center
-
Greeley、Colorado、美国、80631
- 暂停
- Banner North Colorado Medical Center
-
Lafayette、Colorado、美国、80026
- 暂停
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood、Colorado、美国、80228
- 主动,不招人
- Rocky Mountain Cancer Centers-Lakewood
-
Littleton、Colorado、美国、80120
- 主动,不招人
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree、Colorado、美国、80124
- 暂停
- Sky Ridge Medical Center
-
Lone Tree、Colorado、美国、80124
- 主动,不招人
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland、Colorado、美国、80539
- 暂停
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton、Colorado、美国、80260
- 暂停
- National Jewish Health-Northern Hematology Oncology
-
Thornton、Colorado、美国、80260
- 主动,不招人
- Rocky Mountain Cancer Centers-Thornton
-
Wheat Ridge、Colorado、美国、80401
- 暂停
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Hartford、Connecticut、美国、06105
- 暂停
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven、Connecticut、美国、06520
- 招聘中
- Yale University
-
接触:
- Site Public Contact
- 电话号码:203-785-5702
- 邮箱:canceranswers@yale.edu
-
首席研究员:
- Lourdes M. Mendez
-
New Haven、Connecticut、美国、06510
- 暂停
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Florida
-
Fort Lauderdale、Florida、美国、33308
- 暂停
- Holy Cross Hospital
-
Hollywood、Florida、美国、33021
- 招聘中
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:954-265-1847
- 邮箱:OHR@mhs.net
-
首席研究员:
- Fernando M. Vargas Madueno
-
Miami、Florida、美国、33176
- 主动,不招人
- Miami Cancer Institute
-
Orlando、Florida、美国、32806
- 招聘中
- Orlando Health Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:321-841-7246
- 邮箱:CancerClinicalTrials@orlandohealth.com
-
首席研究员:
- Jose E. Sarriera
-
Pembroke Pines、Florida、美国、33028
- 暂停
- Memorial Hospital West
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University Hospital/Winship Cancer Institute
-
首席研究员:
- William G. Blum
-
接触:
- Site Public Contact
- 电话号码:404-778-1868
-
Augusta、Georgia、美国、30912
- 招聘中
- Augusta University Medical Center
-
首席研究员:
- Vamsi Kota
-
接触:
- Site Public Contact
- 电话号码:706-721-2388
- 邮箱:ga_cares@augusta.edu
-
-
Hawaii
-
Hilo、Hawaii、美国、96720
- 暂停
- Island Urology-Hilo
-
Honolulu、Hawaii、美国、96826
- 招聘中
- Kapiolani Medical Center for Women and Children
-
首席研究员:
- Craig S. Boddy
-
接触:
- Site Public Contact
- 电话号码:808-983-6090
-
Honolulu、Hawaii、美国、96813
- 暂停
- Island Urology
-
Honolulu、Hawaii、美国、96813
- 招聘中
- Straub Clinic and Hospital
-
首席研究员:
- Craig S. Boddy
-
接触:
- Site Public Contact
- 电话号码:808-522-4333
-
Honolulu、Hawaii、美国、96813
- 暂停
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu、Hawaii、美国、96813
- 暂停
- Queen's Cancer Cenrer - POB I
-
Honolulu、Hawaii、美国、96813
- 暂停
- Queen's Medical Center
-
Honolulu、Hawaii、美国、96813
- 暂停
- University of Hawaii Cancer Center
-
Honolulu、Hawaii、美国、96817
- 暂停
- Hawaii Cancer Care Inc-Liliha
-
Honolulu、Hawaii、美国、96817
- 暂停
- Kuakini Medical Center
-
Honolulu、Hawaii、美国、96817
- 暂停
- Queen's Cancer Center - Kuakini
-
Honolulu、Hawaii、美国、96817
- 暂停
- The Cancer Center of Hawaii-Liliha
-
Honolulu、Hawaii、美国、96819
- 暂停
- Kaiser Permanente Moanalua Medical Center
-
Lihue、Hawaii、美国、96766
- 暂停
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea、Hawaii、美国、96701
- 招聘中
- Pali Momi Medical Center
-
首席研究员:
- Craig S. Boddy
-
接触:
- Site Public Contact
- 电话号码:808-486-6000
-
‘Aiea、Hawaii、美国、96701
- 暂停
- Queen's Cancer Center - Pearlridge
-
‘Aiea、Hawaii、美国、96701
- 暂停
- The Cancer Center of Hawaii-Pali Momi
-
‘Aiea、Hawaii、美国、96701
- 暂停
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise、Idaho、美国、83712
- 招聘中
- Saint Luke's Cancer Institute - Boise
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:208-381-2774
- 邮箱:eslinget@slhs.org
-
Boise、Idaho、美国、83706
- 招聘中
- Saint Alphonsus Cancer Care Center-Boise
-
接触:
- Site Public Contact
- 电话号码:734-712-3671
- 邮箱:stephanie.couch@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Caldwell、Idaho、美国、83605
- 招聘中
- Saint Alphonsus Cancer Care Center-Caldwell
-
接触:
- Site Public Contact
- 电话号码:734-712-3671
- 邮箱:stephanie.couch@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Coeur d'Alene、Idaho、美国、83814
- 招聘中
- Kootenai Health - Coeur d'Alene
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Emmett、Idaho、美国、83617
- 暂停
- Walter Knox Memorial Hospital
-
Fruitland、Idaho、美国、83619
- 招聘中
- Saint Luke's Cancer Institute - Fruitland
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:208-381-2774
- 邮箱:eslinget@slhs.org
-
Meridian、Idaho、美国、83642
- 暂停
- Idaho Urologic Institute-Meridian
-
Meridian、Idaho、美国、83642
- 招聘中
- Saint Luke's Cancer Institute - Meridian
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:208-381-2774
- 邮箱:eslinget@slhs.org
-
Nampa、Idaho、美国、83687
- 招聘中
- Saint Luke's Cancer Institute - Nampa
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:208-381-2774
- 邮箱:eslinget@slhs.org
-
Nampa、Idaho、美国、83687
- 招聘中
- Saint Alphonsus Cancer Care Center-Nampa
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
首席研究员:
- Tareq Al baghdadi
-
Post Falls、Idaho、美国、83854
- 招聘中
- Kootenai Clinic Cancer Services - Post Falls
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Sandpoint、Idaho、美国、83864
- 招聘中
- Kootenai Clinic Cancer Services - Sandpoint
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Twin Falls、Idaho、美国、83301
- 招聘中
- Saint Luke's Cancer Institute - Twin Falls
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:208-381-2774
- 邮箱:eslinget@slhs.org
-
-
Illinois
-
Alton、Illinois、美国、62002
- 暂停
- OSF Saint Anthony's Health Center
-
Burr Ridge、Illinois、美国、60527
- 暂停
- Loyola Center for Health at Burr Ridge
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago Comprehensive Cancer Center
-
首席研究员:
- Wendy Stock
-
接触:
- Site Public Contact
- 电话号码:773-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University
-
首席研究员:
- Shira N. Dinner
-
接触:
- Site Public Contact
- 电话号码:312-695-1301
- 邮箱:cancer@northwestern.edu
-
Chicago、Illinois、美国、60612
- 招聘中
- University of Illinois
-
接触:
- Site Public Contact
- 电话号码:312-355-3046
-
首席研究员:
- John G. Quigley
-
Chicago、Illinois、美国、60612
- 招聘中
- Rush MD Anderson Cancer Center
-
接触:
- Site Public Contact
- 电话号码:312-226-2371
- 邮箱:Cancer_Studies@rush.edu
-
首席研究员:
- Melissa L. Larson
-
Evanston、Illinois、美国、60201
- 招聘中
- NorthShore University HealthSystem-Evanston Hospital
-
首席研究员:
- Amy Y. Wang
-
接触:
- Site Public Contact
- 电话号码:847-570-2109
-
Glenview、Illinois、美国、60026
- 招聘中
- NorthShore University HealthSystem-Glenbrook Hospital
-
首席研究员:
- Amy Y. Wang
-
接触:
- Site Public Contact
- 电话号码:847-570-2109
-
Highland Park、Illinois、美国、60035
- 招聘中
- NorthShore University HealthSystem-Highland Park Hospital
-
首席研究员:
- Amy Y. Wang
-
接触:
- Site Public Contact
- 电话号码:847-570-2109
-
Homer Glen、Illinois、美国、60491
- 暂停
- Loyola Medicine Homer Glen
-
Lake Forest、Illinois、美国、60045
- 主动,不招人
- Northwestern Medicine Lake Forest Hospital
-
Lisle、Illinois、美国、60532
- 暂停
- Rush MD Anderson Cancer Center at Rush Lisle
-
Maywood、Illinois、美国、60153
- 招聘中
- Loyola University Medical Center
-
首席研究员:
- Patrick A. Hagen
-
接触:
- Site Public Contact
- 电话号码:708-226-4357
-
Melrose Park、Illinois、美国、60160
- 暂停
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon、Illinois、美国、62864
- 暂停
- SSM Health Good Samaritan
-
New Lenox、Illinois、美国、60451
- 招聘中
- UC Comprehensive Cancer Center at Silver Cross
-
首席研究员:
- Wendy Stock
-
接触:
- Site Public Contact
- 电话号码:773-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
Orland Park、Illinois、美国、60462
- 招聘中
- University of Chicago Medicine-Orland Park
-
首席研究员:
- Wendy Stock
-
接触:
- Site Public Contact
- 电话号码:773-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
-
Iowa
-
Carroll、Iowa、美国、51401
- 主动,不招人
- Saint Anthony Regional Hospital
-
Des Moines、Iowa、美国、50314
- 主动,不招人
- Broadlawns Medical Center
-
Des Moines、Iowa、美国、50309
- 主动,不招人
- Iowa Methodist Medical Center
-
Des Moines、Iowa、美国、50316
- 主动,不招人
- Iowa Lutheran Hospital
-
Des Moines、Iowa、美国、50309
- 主动,不招人
- Blank Children's Hospital
-
Des Moines、Iowa、美国、50309
- 主动,不招人
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Fort Dodge、Iowa、美国、50501
- 主动,不招人
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa/Holden Comprehensive Cancer Center
-
首席研究员:
- Grerk Sutamtewagul
-
接触:
- Site Public Contact
- 电话号码:800-237-1225
-
West Des Moines、Iowa、美国、50266-7700
- 主动,不招人
- Methodist West Hospital
-
-
Kansas
-
Garden City、Kansas、美国、67846
- 暂停
- Central Care Cancer Center - Garden City
-
Great Bend、Kansas、美国、67530
- 暂停
- Central Care Cancer Center - Great Bend
-
Kansas City、Kansas、美国、66160
- 招聘中
- University of Kansas Cancer Center
-
首席研究员:
- Kenneth Byrd
-
接触:
- Site Public Contact
- 电话号码:913-588-3671
- 邮箱:KUCC_Navigation@kumc.edu
-
Lawrence、Kansas、美国、66044
- 暂停
- Lawrence Memorial Hospital
-
Westwood、Kansas、美国、66205
- 招聘中
- University of Kansas Hospital-Westwood Cancer Center
-
首席研究员:
- Kenneth Byrd
-
接触:
- Site Public Contact
- 电话号码:913-588-3671
- 邮箱:KUCC_Navigation@kumc.edu
-
Wichita、Kansas、美国、67214
- 招聘中
- Cancer Center of Kansas - Wichita
-
接触:
- Site Public Contact
- 电话号码:316-291-4774
- 邮箱:research@viachristi.org
-
首席研究员:
- Dennis F. Moore
-
Wichita、Kansas、美国、67208
- 暂停
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、美国、67214
- 暂停
- Ascension Via Christi Hospitals Wichita
-
Wichita、Kansas、美国、67214
- 暂停
- Wesley Medical Center
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 招聘中
- University of Kentucky/Markey Cancer Center
-
接触:
- Site Public Contact
- 电话号码:859-257-3379
-
首席研究员:
- Ayman Qasrawi
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70809
- 主动,不招人
- Ochsner Health Center-Summa
-
Baton Rouge、Louisiana、美国、70816
- 主动,不招人
- Medical Center of Baton Rouge
-
Baton Rouge、Louisiana、美国、70836
- 主动,不招人
- Ochsner High Grove
-
New Orleans、Louisiana、美国、70121
- 主动,不招人
- Ochsner Medical Center Jefferson
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- 招聘中
- University of Maryland/Greenebaum Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-888-8823
-
首席研究员:
- Shella Saint Fleur-Lominy
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 暂停
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、美国、02114
- 暂停
- Massachusetts General Hospital Cancer Center
-
Boston、Massachusetts、美国、02215
- 暂停
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、美国、48106
- 招聘中
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Battle Creek、Michigan、美国、49017
- 暂停
- Bronson Battle Creek
-
Brighton、Michigan、美国、48114
- 招聘中
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Brighton、Michigan、美国、48114
- 招聘中
- Trinity Health Medical Center - Brighton
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Canton、Michigan、美国、48188
- 招聘中
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Canton、Michigan、美国、48188
- 招聘中
- Trinity Health Medical Center - Canton
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Caro、Michigan、美国、48723
- 暂停
- Caro Cancer Center
-
Chelsea、Michigan、美国、48118
- 招聘中
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Chelsea、Michigan、美国、48118
- 招聘中
- Chelsea Hospital
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Clarkston、Michigan、美国、48346
- 暂停
- Hematology Oncology Consultants-Clarkston
-
Clarkston、Michigan、美国、48346
- 暂停
- Newland Medical Associates-Clarkston
-
Detroit、Michigan、美国、48201
- 招聘中
- Wayne State University/Karmanos Cancer Institute
-
首席研究员:
- Jay Yang
-
接触:
- Site Public Contact
- 电话号码:800-527-6266
- 邮箱:ctoadmin@karmanos.org
-
Detroit、Michigan、美国、48236
- 暂停
- Henry Ford Health Saint John Hospital
-
East China Township、Michigan、美国、48054
- 暂停
- Henry Ford River District Hospital
-
Farmington Hills、Michigan、美国、48334
- 招聘中
- Weisberg Cancer Treatment Center
-
首席研究员:
- Jay Yang
-
接触:
- Site Public Contact
- 电话号码:313-576-9790
- 邮箱:ctoadmin@karmanos.org
-
Flint、Michigan、美国、48503
- 招聘中
- Genesys Hurley Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:810-762-8038
- 邮箱:wstrong@ghci.org
-
首席研究员:
- Tareq Al baghdadi
-
Flint、Michigan、美国、48503
- 招聘中
- Hurley Medical Center
-
接触:
- Site Public Contact
- 电话号码:810-762-8038
- 邮箱:wstrong@ghci.org
-
首席研究员:
- Tareq Al baghdadi
-
Flint、Michigan、美国、48503
- 暂停
- Genesee Hematology Oncology PC
-
Flint、Michigan、美国、48503
- 招聘中
- Cancer Hematology Centers - Flint
-
接触:
- Site Public Contact
- 电话号码:810-762-8038
- 邮箱:wstrong@ghci.org
-
首席研究员:
- Tareq Al baghdadi
-
Grand Rapids、Michigan、美国、49503
- 招聘中
- Trinity Health Grand Rapids Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Tareq Al baghdadi
-
Grand Rapids、Michigan、美国、49503
- 招聘中
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Grand Rapids、Michigan、美国、49503
- 暂停
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grosse Pointe Woods、Michigan、美国、48236
- 暂停
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods、Michigan、美国、48236
- 暂停
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods、Michigan、美国、48236
- 暂停
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo、Michigan、美国、49007
- 招聘中
- Bronson Methodist Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Kalamazoo、Michigan、美国、49007
- 招聘中
- West Michigan Cancer Center
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Kalamazoo、Michigan、美国、49009
- 招聘中
- Beacon Kalamazoo Cancer Center
-
首席研究员:
- Kathleen Y. Butler
-
接触:
- Site Public Contact
- 电话号码:574-647-7370
-
Kalamazoo、Michigan、美国、49048
- 暂停
- Beacon Kalamazoo
-
Lansing、Michigan、美国、48912
- 暂停
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、美国、48154
- 暂停
- Hope Cancer Clinic
-
Livonia、Michigan、美国、48154
- 招聘中
- Trinity Health Saint Mary Mercy Livonia Hospital
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Macomb、Michigan、美国、48044
- 暂停
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb、Michigan、美国、48044
- 招聘中
- Henry Ford Saint John Hospital - Macomb Medical
-
首席研究员:
- Tareq Al baghdadi
-
接触:
- Site Public Contact
- 电话号码:313-343-3166
- 邮箱:kforman1@hfhs.org
-
Marlette、Michigan、美国、48453
- 暂停
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Muskegon、Michigan、美国、49444
- 暂停
- Trinity Health Muskegon Hospital
-
Niles、Michigan、美国、49120
- 招聘中
- Corewell Health Lakeland Hospitals - Niles Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
-
首席研究员:
- Kathleen Y. Butler
-
Norton Shores、Michigan、美国、49444
- 暂停
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Pontiac、Michigan、美国、48341
- 暂停
- Hope Cancer Center
-
Pontiac、Michigan、美国、48341
- 招聘中
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Pontiac、Michigan、美国、48341
- 暂停
- Michigan Healthcare Professionals Pontiac
-
Pontiac、Michigan、美国、48341
- 暂停
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Reed City、Michigan、美国、49677
- 招聘中
- Corewell Health Reed City Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Rochester Hills、Michigan、美国、48309
- 暂停
- Henry Ford Rochester Hospital
-
Saginaw、Michigan、美国、48604
- 暂停
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、美国、48601
- 暂停
- MyMichigan Medical Center Saginaw
-
Saint Joseph、Michigan、美国、49085
- 招聘中
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Saint Joseph、Michigan、美国、49085
- 暂停
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Sterling Heights、Michigan、美国、48312
- 暂停
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City、Michigan、美国、48764
- 暂停
- MyMichigan Medical Center Tawas
-
Traverse City、Michigan、美国、49684
- 招聘中
- Munson Medical Center
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Warren、Michigan、美国、48088
- 暂停
- Advanced Breast Care Center PLLC
-
Warren、Michigan、美国、48093
- 暂停
- Macomb Hematology Oncology PC
-
Warren、Michigan、美国、48093
- 暂停
- Henry Ford Madison Heights Hospital - Breast
-
Warren、Michigan、美国、48093
- 暂停
- Henry Ford Health Warren Hospital
-
Warren、Michigan、美国、48093
- 暂停
- Henry Ford Warren Hospital - GLCMS
-
West Branch、Michigan、美国、48661
- 暂停
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming、Michigan、美国、49519
- 招聘中
- University of Michigan Health - West
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
Ypsilanti、Michigan、美国、48106
- 招聘中
- Huron Gastroenterology PC
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
Ypsilanti、Michigan、美国、48197
- 招聘中
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
接触:
- Site Public Contact
- 电话号码:734-712-7251
- 邮箱:MCRCwebsitecontactform@stjoeshealth.org
-
首席研究员:
- Tareq Al baghdadi
-
-
Minnesota
-
Aitkin、Minnesota、美国、56431
- 暂停
- Riverwood Healthcare Center
-
Brainerd、Minnesota、美国、56401
- 暂停
- Essentia Health Saint Joseph's Medical Center
-
Burnsville、Minnesota、美国、55337
- 暂停
- Fairview Ridges Hospital
-
Burnsville、Minnesota、美国、55337
- 暂停
- Minnesota Oncology - Burnsville
-
Cambridge、Minnesota、美国、55008
- 暂停
- Cambridge Medical Center
-
Coon Rapids、Minnesota、美国、55433
- 暂停
- Mercy Hospital
-
Deer River、Minnesota、美国、56636
- 暂停
- Essentia Health - Deer River Clinic
-
Detroit Lakes、Minnesota、美国、56501
- 暂停
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth、Minnesota、美国、55805
- 招聘中
- Essentia Health Cancer Center
-
接触:
- Site Public Contact
- 电话号码:218-786-3308
- 邮箱:CancerTrials@EssentiaHealth.org
-
首席研究员:
- Bret E. Friday
-
Duluth、Minnesota、美国、55805
- 暂停
- Essentia Health Saint Mary's Medical Center
-
Duluth、Minnesota、美国、55805
- 暂停
- Miller-Dwan Hospital
-
Edina、Minnesota、美国、55435
- 暂停
- Fairview Southdale Hospital
-
Fergus Falls、Minnesota、美国、56537
- 暂停
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston、Minnesota、美国、56542
- 暂停
- Essentia Health - Fosston
-
Fridley、Minnesota、美国、55432
- 主动,不招人
- Unity Hospital
-
Hibbing、Minnesota、美国、55746
- 暂停
- Essentia Health Hibbing Clinic
-
Maple Grove、Minnesota、美国、55369
- 暂停
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood、Minnesota、美国、55109
- 暂停
- Minnesota Oncology Hematology PA-Maplewood
-
Maplewood、Minnesota、美国、55109
- 暂停
- Saint John's Hospital - Healtheast
-
Minneapolis、Minnesota、美国、55407
- 招聘中
- Abbott-Northwestern Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Minneapolis、Minnesota、美国、55415
- 暂停
- Hennepin County Medical Center
-
Minneapolis、Minnesota、美国、55454
- 暂停
- Health Partners Inc
-
Monticello、Minnesota、美国、55362
- 暂停
- Monticello Cancer Center
-
New Ulm、Minnesota、美国、56073
- 暂停
- New Ulm Medical Center
-
Park Rapids、Minnesota、美国、56470
- 暂停
- Essentia Health - Park Rapids
-
Princeton、Minnesota、美国、55371
- 暂停
- Fairview Northland Medical Center
-
Robbinsdale、Minnesota、美国、55422
- 暂停
- North Memorial Medical Health Center
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic in Rochester
-
接触:
- Site Public Contact
- 电话号码:855-776-0015
-
首席研究员:
- Aasiya Matin
-
Saint Louis Park、Minnesota、美国、55416
- 暂停
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、美国、55102
- 暂停
- United Hospital
-
Saint Paul、Minnesota、美国、55101
- 暂停
- Regions Hospital
-
Sandstone、Minnesota、美国、55072
- 暂停
- Essentia Health Sandstone
-
Shakopee、Minnesota、美国、55379
- 暂停
- Saint Francis Regional Medical Center
-
Stillwater、Minnesota、美国、55082
- 暂停
- Lakeview Hospital
-
Virginia、Minnesota、美国、55792
- 暂停
- Essentia Health Virginia Clinic
-
Waconia、Minnesota、美国、55387
- 暂停
- Ridgeview Medical Center
-
Willmar、Minnesota、美国、56201
- 暂停
- Rice Memorial Hospital
-
Woodbury、Minnesota、美国、55125
- 暂停
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming、Minnesota、美国、55092
- 暂停
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin、Missouri、美国、63011
- 暂停
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar、Missouri、美国、65613
- 暂停
- Central Care Cancer Center - Bolivar
-
Branson、Missouri、美国、65616
- 暂停
- Cox Cancer Center Branson
-
City of Saint Peters、Missouri、美国、63376
- 招聘中
- Siteman Cancer Center at Saint Peters Hospital
-
首席研究员:
- Geoffrey L. Uy
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
Creve Coeur、Missouri、美国、63141
- 招聘中
- Siteman Cancer Center at West County Hospital
-
首席研究员:
- Geoffrey L. Uy
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
Joplin、Missouri、美国、64804
- 暂停
- Freeman Health System
-
Joplin、Missouri、美国、64804
- 暂停
- Mercy Hospital Joplin
-
Rolla、Missouri、美国、65401
- 暂停
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla、Missouri、美国、65401
- 暂停
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph、Missouri、美国、64506
- 暂停
- Heartland Regional Medical Center
-
Springfield、Missouri、美国、65804
- 暂停
- Mercy Hospital Springfield
-
Springfield、Missouri、美国、65807
- 暂停
- CoxHealth South Hospital
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
首席研究员:
- Geoffrey L. Uy
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
St Louis、Missouri、美国、63128
- 招聘中
- Mercy Hospital South
-
首席研究员:
- Jay W. Carlson
-
接触:
- Site Public Contact
- 电话号码:314-525-6042
- 邮箱:Danielle.Werle@mercy.net
-
St Louis、Missouri、美国、63141
- 招聘中
- Mercy Hospital Saint Louis
-
首席研究员:
- Jay W. Carlson
-
接触:
- Site Public Contact
- 电话号码:314-251-7066
-
St Louis、Missouri、美国、63129
- 招聘中
- Siteman Cancer Center-South County
-
首席研究员:
- Geoffrey L. Uy
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
St Louis、Missouri、美国、63109
- 暂停
- Mercy Infusion Center - Chippewa
-
Washington、Missouri、美国、63090
- 暂停
- Mercy Hospital Washington
-
-
Montana
-
Anaconda、Montana、美国、59711
- 招聘中
- Community Hospital of Anaconda
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Billings、Montana、美国、59101
- 招聘中
- Billings Clinic Cancer Center
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:800-996-2663
- 邮箱:research@billingsclinic.org
-
Billings、Montana、美国、59101
- 暂停
- Saint Vincent Healthcare
-
Billings、Montana、美国、59102
- 暂停
- Saint Vincent Frontier Cancer Center
-
Bozeman、Montana、美国、59715
- 招聘中
- Bozeman Health Deaconess Hospital
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Butte、Montana、美国、59701
- 暂停
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls、Montana、美国、59405
- 暂停
- Great Falls Clinic
-
Great Falls、Montana、美国、59405
- 招聘中
- Benefis Sletten Cancer Institute
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Kalispell、Montana、美国、59901
- 招聘中
- Logan Health Medical Center
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
Missoula、Montana、美国、59802
- 暂停
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、美国、59804
- 招聘中
- Community Medical Center
-
首席研究员:
- John M. Schallenkamp
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue、Nebraska、美国、68123
- 招聘中
- Nebraska Medicine-Bellevue
-
首席研究员:
- Krishna Gundabolu
-
接触:
- Site Public Contact
- 电话号码:402-559-6941
- 邮箱:unmcrsa@unmc.edu
-
Omaha、Nebraska、美国、68198
- 招聘中
- University of Nebraska Medical Center
-
首席研究员:
- Krishna Gundabolu
-
接触:
- Site Public Contact
- 电话号码:402-559-6941
- 邮箱:unmcrsa@unmc.edu
-
Omaha、Nebraska、美国、68118
- 招聘中
- Nebraska Medicine-Village Pointe
-
首席研究员:
- Krishna Gundabolu
-
接触:
- Site Public Contact
- 电话号码:402-559-5600
-
-
Nevada
-
Carson City、Nevada、美国、89703
- 暂停
- Carson Tahoe Regional Medical Center
-
Henderson、Nevada、美国、89052
- 暂停
- Cancer and Blood Specialists-Henderson
-
Henderson、Nevada、美国、89052
- 暂停
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson、Nevada、美国、89052
- 暂停
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson、Nevada、美国、89052
- 暂停
- Las Vegas Cancer Center-Henderson
-
Henderson、Nevada、美国、89074
- 暂停
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson、Nevada、美国、89074
- 暂停
- Las Vegas Urology - Green Valley
-
Henderson、Nevada、美国、89074
- 暂停
- Las Vegas Urology - Pebble
-
Henderson、Nevada、美国、89074
- 暂停
- Urology Specialists of Nevada - Green Valley
-
Henderson、Nevada、美国、89074
- 暂停
- Oncology Las Vegas - Henderson
-
Las Vegas、Nevada、美国、89102
- 暂停
- Desert West Surgery
-
Las Vegas、Nevada、美国、89074
- 暂停
- Las Vegas Urology - Pecos
-
Las Vegas、Nevada、美国、89102
- 暂停
- University Medical Center of Southern Nevada
-
Las Vegas、Nevada、美国、89103
- 暂停
- Hope Cancer Care of Nevada
-
Las Vegas、Nevada、美国、89106
- 暂停
- Radiation Oncology Centers of Nevada Central
-
Las Vegas、Nevada、美国、89106
- 暂停
- Urology Specialists of Nevada - Central
-
Las Vegas、Nevada、美国、89109
- 暂停
- Sunrise Hospital and Medical Center
-
Las Vegas、Nevada、美国、89113
- 暂停
- Las Vegas Prostate Cancer Center
-
Las Vegas、Nevada、美国、89113
- 暂停
- Las Vegas Urology - Sunset
-
Las Vegas、Nevada、美国、89113
- 暂停
- Urology Specialists of Nevada - Southwest
-
Las Vegas、Nevada、美国、89119
- 暂停
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas、Nevada、美国、89128
- 暂停
- Ann M Wierman MD LTD
-
Las Vegas、Nevada、美国、89128
- 暂停
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas、Nevada、美国、89128
- 暂停
- Las Vegas Urology - Cathedral Rock
-
Las Vegas、Nevada、美国、89128
- 暂停
- Las Vegas Urology - Smoke Ranch
-
Las Vegas、Nevada、美国、89128
- 暂停
- OptumCare Cancer Care at MountainView
-
Las Vegas、Nevada、美国、89128
- 暂停
- Urology Specialists of Nevada - Northwest
-
Las Vegas、Nevada、美国、89135
- 暂停
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、美国、89144
- 暂停
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas、Nevada、美国、89144
- 暂停
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas、Nevada、美国、89144
- 暂停
- Summerlin Hospital Medical Center
-
Las Vegas、Nevada、美国、89148-2405
- 暂停
- Las Vegas Cancer Center-Medical Center
-
Las Vegas、Nevada、美国、89148
- 暂停
- Comprehensive Cancer Centers of Nevada
-
Las Vegas、Nevada、美国、89169
- 暂停
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas、Nevada、美国、89169
- 暂停
- University Cancer Center
-
Las Vegas、Nevada、美国、89102
- 暂停
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、美国、89128
- 暂停
- Oncology Las Vegas - Tenaya
-
Las Vegas、Nevada、美国、89183
- 暂停
- OptumCare Cancer Care at Fort Apache
-
Pahrump、Nevada、美国、89048
- 暂停
- Hope Cancer Care of Nevada-Pahrump
-
Reno、Nevada、美国、89502
- 暂停
- Renown Regional Medical Center
-
Reno、Nevada、美国、89503
- 暂停
- Saint Mary's Regional Medical Center
-
Reno、Nevada、美国、89509
- 暂停
- Radiation Oncology Associates
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- 主动,不招人
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Cancer Institute
-
首席研究员:
- Eunice S. Wang
-
接触:
- Site Public Contact
- 电话号码:800-767-9355
- 邮箱:askroswell@roswellpark.org
-
Lake Success、New York、美国、11042
- 招聘中
- Northwell Health/Center for Advanced Medicine
-
接触:
- Site Public Contact
- 电话号码:516-734-8896
-
首席研究员:
- Bradley H. Goldberg
-
Manhasset、New York、美国、11030
- 招聘中
- North Shore University Hospital
-
接触:
- Site Public Contact
- 电话号码:516-734-8896
-
首席研究员:
- Bradley H. Goldberg
-
New Hyde Park、New York、美国、11040
- 招聘中
- Long Island Jewish Medical Center
-
接触:
- Site Public Contact
- 电话号码:516-734-8896
-
首席研究员:
- Bradley H. Goldberg
-
New York、New York、美国、10029
- 招聘中
- Mount Sinai Hospital
-
接触:
- Site Public Contact
- 电话号码:212-824-7309
- 邮箱:CCTO@mssm.edu
-
首席研究员:
- Hannah Levavi
-
New York、New York、美国、10065
- 招聘中
- NYP/Weill Cornell Medical Center
-
接触:
- Site Public Contact
- 电话号码:212-746-1848
-
首席研究员:
- Gail J. Roboz
-
Rochester、New York、美国、14642
- 招聘中
- University of Rochester
-
接触:
- Site Public Contact
- 电话号码:585-275-5830
-
首席研究员:
- Kristen M. O'Dwyer
-
Stony Brook、New York、美国、11794
- 主动,不招人
- Stony Brook University Medical Center
-
Syracuse、New York、美国、13210
- 主动,不招人
- State University of New York Upstate Medical University
-
Verona、New York、美国、13478
- 主动,不招人
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- 招聘中
- UNC Lineberger Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:877-668-0683
- 邮箱:cancerclinicaltrials@med.unc.edu
-
首席研究员:
- Daniel R. Richardson
-
Durham、North Carolina、美国、27710
- 主动,不招人
- Duke University Medical Center
-
Greenville、North Carolina、美国、27834
- 招聘中
- East Carolina University
-
首席研究员:
- Darla K. Liles
-
接触:
- Site Public Contact
- 电话号码:252-744-1015
- 邮箱:eubankss@ecu.edu
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University Health Sciences
-
接触:
- Site Public Contact
- 电话号码:336-713-6771
-
首席研究员:
- Bayard L. Powell
-
-
North Dakota
-
Fargo、North Dakota、美国、58103
- 暂停
- Essentia Health Cancer Center-South University Clinic
-
Jamestown、North Dakota、美国、58401
- 暂停
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- 招聘中
- University of Cincinnati Cancer Center-UC Medical Center
-
首席研究员:
- Emily K. Curran
-
接触:
- Site Public Contact
- 电话号码:513-584-7698
- 邮箱:cancer@uchealth.com
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic Foundation
-
接触:
- Site Public Contact
- 电话号码:866-223-8100
- 邮箱:TaussigResearch@ccf.org
-
首席研究员:
- Anjali S. Advani
-
Cleveland、Ohio、美国、44106
- 招聘中
- Case Western Reserve University
-
首席研究员:
- Brenda W. Cooper
-
接触:
- Site Public Contact
- 电话号码:800-641-2422
- 邮箱:CTUReferral@UHhospitals.org
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University Comprehensive Cancer Center
-
首席研究员:
- Meixiao Long
-
接触:
- Site Public Contact
- 电话号码:800-293-5066
- 邮箱:Jamesline@osumc.edu
-
West Chester、Ohio、美国、45069
- 招聘中
- University of Cincinnati Cancer Center-West Chester
-
首席研究员:
- Emily K. Curran
-
接触:
- Site Public Contact
- 电话号码:513-584-7698
- 邮箱:cancer@uchealth.com
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma Health Sciences Center
-
接触:
- Site Public Contact
- 电话号码:405-271-8777
- 邮箱:ou-clinical-trials@ouhsc.edu
-
首席研究员:
- Mohamad Khawandanah
-
Oklahoma City、Oklahoma、美国、73120
- 暂停
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Baker City、Oregon、美国、97814
- 暂停
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend、Oregon、美国、97701
- 暂停
- Saint Charles Health System
-
Clackamas、Oregon、美国、97015
- 暂停
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、美国、97015
- 暂停
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay、Oregon、美国、97420
- 暂停
- Bay Area Hospital
-
Newberg、Oregon、美国、97132
- 招聘中
- Providence Newberg Medical Center
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:503-215-2614
- 邮箱:CanRsrchStudies@providence.org
-
Ontario、Oregon、美国、97914
- 招聘中
- Saint Alphonsus Cancer Care Center-Ontario
-
接触:
- Site Public Contact
- 电话号码:406-969-6060
- 邮箱:mccinfo@mtcancer.org
-
首席研究员:
- Tareq Al baghdadi
-
Portland、Oregon、美国、97239
- 招聘中
- Oregon Health and Science University
-
接触:
- Site Public Contact
- 电话号码:503-494-1080
- 邮箱:trials@ohsu.edu
-
首席研究员:
- Brandon M. Hayes-Lattin
-
Portland、Oregon、美国、97213
- 招聘中
- Providence Portland Medical Center
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:503-215-2614
- 邮箱:CanRsrchStudies@providence.org
-
Portland、Oregon、美国、97225
- 招聘中
- Providence Saint Vincent Medical Center
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:503-215-2614
- 邮箱:CanRsrchStudies@providence.org
-
Redmond、Oregon、美国、97756
- 暂停
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- 招聘中
- Lehigh Valley Hospital-Cedar Crest
-
接触:
- Site Public Contact
- 电话号码:610-402-9543
- 邮箱:Morgan_M.Horton@lvhn.org
-
首席研究员:
- Tareq Al baghdadi
-
Bethlehem、Pennsylvania、美国、18017
- 招聘中
- Lehigh Valley Hospital - Muhlenberg
-
接触:
- Site Public Contact
- 电话号码:610-402-9543
- 邮箱:Morgan_M.Horton@lvhn.org
-
首席研究员:
- Tareq Al baghdadi
-
East Stroudsburg、Pennsylvania、美国、18301
- 暂停
- Pocono Medical Center
-
Hazleton、Pennsylvania、美国、18201
- 暂停
- Lehigh Valley Hospital-Hazleton
-
Philadelphia、Pennsylvania、美国、19107
- 招聘中
- Thomas Jefferson University Hospital
-
首席研究员:
- Lindsay Wilde
-
接触:
- Site Public Contact
- 电话号码:215-600-9151
- 邮箱:ONCTrialNow@jefferson.edu
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- University of Pennsylvania/Abramson Cancer Center
-
首席研究员:
- Keith W. Pratz
-
接触:
- Site Public Contact
- 电话号码:215-349-8245
- 邮箱:PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh、Pennsylvania、美国、15232
- 主动,不招人
- UPMC Hillman Cancer Center
-
-
Rhode Island
-
Providence、Rhode Island、美国、02903
- 招聘中
- Rhode Island Hospital
-
接触:
- Site Public Contact
- 电话号码:401-444-1488
-
首席研究员:
- Rabin Niroula
-
Providence、Rhode Island、美国、02906
- 暂停
- Miriam Hospital
-
-
South Carolina
-
Boiling Springs、South Carolina、美国、29316
- 招聘中
- Prisma Health Cancer Institute - Spartanburg
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Clinton、South Carolina、美国、29325
- 暂停
- Prisma Health Cancer Institute - Laurens
-
Columbia、South Carolina、美国、29203
- 招聘中
- Prisma Health Richland Hospital
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Easley、South Carolina、美国、29640
- 招聘中
- Prisma Health Cancer Institute - Easley
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29601
- 招聘中
- Saint Francis Hospital
-
首席研究员:
- Stephen H. Dyar
-
接触:
- Site Public Contact
- 电话号码:864-603-6234
- 邮箱:Heather_Rich@bshsi.org
-
Greenville、South Carolina、美国、29605
- 招聘中
- Prisma Health Cancer Institute - Faris
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29607
- 招聘中
- Saint Francis Cancer Center
-
首席研究员:
- Stephen H. Dyar
-
接触:
- Site Public Contact
- 电话号码:864-603-6234
- 邮箱:Heather_Rich@bshsi.org
-
Greenville、South Carolina、美国、29605
- 招聘中
- Prisma Health Cancer Institute - Butternut
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29615
- 招聘中
- Prisma Health Cancer Institute - Eastside
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29605
- 招聘中
- Prisma Health Greenville Memorial Hospital
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29605
- 暂停
- BI-LO Charities Children's Cancer Center
-
Greer、South Carolina、美国、29650
- 招聘中
- Prisma Health Cancer Institute - Greer
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Seneca、South Carolina、美国、29672
- 招聘中
- Prisma Health Cancer Institute - Seneca
-
首席研究员:
- Ki Y. Chung
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Houston Methodist Hospital
-
首席研究员:
- Siddhartha Ganguly
-
接触:
- Site Public Contact
- 电话号码:713-790-2700
-
Lubbock、Texas、美国、79410
- 主动,不招人
- Covenant Medical Center-Lakeside
-
-
Utah
-
American Fork、Utah、美国、84003
- 暂停
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City、Utah、美国、84720
- 暂停
- Sandra L Maxwell Cancer Center
-
Logan、Utah、美国、84321
- 暂停
- Logan Regional Hospital
-
Murray、Utah、美国、84107
- 暂停
- Intermountain Medical Center
-
Ogden、Utah、美国、84403
- 暂停
- McKay-Dee Hospital Center
-
Provo、Utah、美国、84604
- 暂停
- Utah Valley Regional Medical Center
-
Riverton、Utah、美国、84065
- 暂停
- Riverton Hospital
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute/University of Utah
-
接触:
- Site Public Contact
- 电话号码:888-424-2100
- 邮箱:cancerinfo@hci.utah.edu
-
首席研究员:
- Paul J. Shami
-
Salt Lake City、Utah、美国、84106
- 暂停
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City、Utah、美国、84143
- 暂停
- LDS Hospital
-
St. George、Utah、美国、84770
- 暂停
- Saint George Regional Medical Center
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 主动,不招人
- Inova Schar Cancer Institute
-
Falls Church、Virginia、美国、22042
- 主动,不招人
- Inova Fairfax Hospital
-
Richmond、Virginia、美国、23298
- 招聘中
- VCU Massey Comprehensive Cancer Center
-
首席研究员:
- Keri R. Maher
-
接触:
- Site Public Contact
- 电话号码:804-628-6430
- 邮箱:CTOclinops@vcu.edu
-
-
Washington
-
Aberdeen、Washington、美国、98520
- 暂停
- Providence Regional Cancer System-Aberdeen
-
Bellevue、Washington、美国、98004
- 暂停
- Overlake Medical Center
-
Bellingham、Washington、美国、98225
- 暂停
- PeaceHealth Saint Joseph Medical Center
-
Centralia、Washington、美国、98531
- 暂停
- Providence Regional Cancer System-Centralia
-
Edmonds、Washington、美国、98026
- 招聘中
- Swedish Cancer Institute-Edmonds
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:206-215-2343
- 邮箱:PCRC-NCORP@Swedish.org
-
Everett、Washington、美国、98201
- 暂停
- Providence Regional Cancer Partnership
-
Issaquah、Washington、美国、98029
- 暂停
- Swedish Cancer Institute-Issaquah
-
Kennewick、Washington、美国、99336
- 暂停
- Kadlec Clinic Hematology and Oncology
-
Lacey、Washington、美国、98503
- 暂停
- Providence Regional Cancer System-Lacey
-
Longview、Washington、美国、98632
- 暂停
- PeaceHealth Saint John Medical Center
-
Port Townsend、Washington、美国、98368
- 主动,不招人
- Jefferson Healthcare
-
Renton、Washington、美国、98055
- 暂停
- Valley Medical Center
-
Seattle、Washington、美国、98104
- 暂停
- Pacific Gynecology Specialists
-
Seattle、Washington、美国、98107
- 暂停
- Swedish Medical Center-Ballard Campus
-
Seattle、Washington、美国、98122-5711
- 暂停
- Swedish Medical Center-Cherry Hill
-
Seattle、Washington、美国、98122
- 招聘中
- Swedish Medical Center-First Hill
-
首席研究员:
- Alison K. Conlin
-
接触:
- Site Public Contact
- 电话号码:206-215-2343
- 邮箱:PCRC-NCORP@Swedish.org
-
Seattle、Washington、美国、98112
- 主动,不招人
- Kaiser Permanente Washington
-
Sedro-Woolley、Washington、美国、98284
- 暂停
- PeaceHealth United General Medical Center
-
Shelton、Washington、美国、98584
- 暂停
- Providence Regional Cancer System-Shelton
-
Vancouver、Washington、美国、98664
- 暂停
- PeaceHealth Southwest Medical Center
-
Walla Walla、Washington、美国、99362
- 暂停
- Providence Saint Mary Regional Cancer Center
-
Yakima、Washington、美国、98902
- 暂停
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm、Washington、美国、98597
- 暂停
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Ashland、Wisconsin、美国、54806
- 暂停
- Northwest Wisconsin Cancer Center
-
Ashland、Wisconsin、美国、54806
- 暂停
- Duluth Clinic Ashland
-
Hayward、Wisconsin、美国、54843
- 暂停
- Essentia Health-Hayward Clinic
-
Madison、Wisconsin、美国、53792
- 招聘中
- University of Wisconsin Carbone Cancer Center - University Hospital
-
首席研究员:
- Ryan J. Mattison
-
接触:
- Site Public Contact
- 电话号码:800-622-8922
- 邮箱:clinicaltrials@cancer.wisc.edu
-
Madison、Wisconsin、美国、53718
- 招聘中
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
首席研究员:
- Ryan J. Mattison
-
接触:
- Site Public Contact
- 电话号码:800-622-8922
- 邮箱:clinicaltrials@cancer.wisc.edu
-
Marshfield、Wisconsin、美国、54449
- 招聘中
- Marshfield Medical Center-Marshfield
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Chady A. Leon
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Medical College of Wisconsin
-
接触:
- Site Public Contact
- 电话号码:414-805-3666
-
首席研究员:
- Guru Subramanian Guru Murthy
-
New Richmond、Wisconsin、美国、54017
- 暂停
- Cancer Center of Western Wisconsin
-
Spooner、Wisconsin、美国、54801
- 暂停
- Essentia Health-Spooner Clinic
-
Superior、Wisconsin、美国、54880
- 暂停
- Essentia Health Saint Mary's Hospital - Superior
-
-
Wyoming
-
Cheyenne、Wyoming、美国、82001
- 主动,不招人
- Cheyenne Regional Medical Center-West
-
Cody、Wyoming、美国、82414
- 暂停
- Billings Clinic-Cody
-
Sheridan、Wyoming、美国、82801
- 暂停
- Welch Cancer Center
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
-
Newly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (WHO criteria) are eligible. Patients with Burkitt type ALL are NOT eligible
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Single-dose intrathecal cytarabine is allowed prior to registration or prior to initiation of systematic therapy for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; systemic chemotherapy must begin within 72 hours of this intrathecal therapy
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age >= 18 years and < 40 years
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Direct bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Completion of remission induction therapy
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) CONFIRMATION OF TOLERABILITY AND PHASE III ONLY):Patients with M2 marrow or better are eligible; patients with M3 or M4 marrow (greater than 25% lymphoblasts) will not be eligible to be randomized
- Rating: M0, M1; Blast Cells (%): 0-5.0
- Rating: M2; Blast Cells (%): 5.1-25.0
- Rating: M3; Blast Cells (%): > 25-50
- Rating: M4; Blast Cells (%): > 50.0
- The term "blast cell" includes any cell that cannot be classified as a more mature normal element, and includes "leukemic cells," pathologic lymphocytes, and stem cells
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Absolute neutrophil count (ANC) >= 750/mm^3
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Platelet count >= 75,000/mm^3
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known Gilbert's syndrome
-
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Aspartate aminotransferase (AST) =< 8 x upper limit of normal (ULN)
EXCLUSION CRITERIA
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients who have BCR-ABL fusion transcript determined by fluorescence in situ hybridization (FISH) or real time-polymerase chain reaction (RT-PCR) or t(9;22)(q34;q11) by cytogenetics are not eligible and should be considered for enrollment on studies that incorporate imatinib during induction; please note: patients must also be assessed for CD20 positivity and other markers; positivity for CD22 and CD20 is defined as baseline expression of the CD22 or CD20 antigen in more than 20% of leukemic cells using local multiparameter flow-cytometric immunophenotyping with the use of CD45 expression as a marker to gate the ALL blast population, according to recommendations from the European LeukemiaNet
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior therapy for ALL except for limited treatment (=< 7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine; however, patients who are being treated with chronic steroids for other reasons (for example, to treat asthma, autoimmune disorders, lupus, etc.) are eligible
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys; when indicated, leukapheresis or exchange transfusion is recommended to reduce the WBC
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is required
- REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients with down syndrome are excluded from this study due to the likelihood of excessive toxicity resulting; these patients should be treated in consultation with a pediatric oncologist
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
有源比较器:Arm I (frontline chemotherapy)
See detailed description. |
Correlative studies Given IV Given IV Given IV Given IV Given PO Given PO or IV Given PO Given PO Given IT, IV, SC Given IV Given IT, IV, PO Undergo bone marrow aspiration and biopsy |
|
实验性的:Arm II (frontline chemotherapy, inotuzumab ozogamicin)
Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who are MRD+ and CD19+ after completion of 2 cycles of inotuzumab ozogamicin receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I. Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study. |
Correlative studies Given IV Given IV Given IV Given IV Given IV Given PO Given IV Given PO or IV Given PO Given PO Given IT, IV, SC Given IV Given IT, IV, PO Undergo bone marrow aspiration and biopsy |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event-free survival (EFS)
大体时间:Time from induction response to the time of progressive-disease, secondary malignancy, or death, assessed up to 3 years
|
The EFS distributions between the two arms will be compared using non-stratified log-rank tests. EFS curves will be constructed using the Kaplan-Meier product limit method, and additional analyses will be done using the Cox proportional hazards model. with diagnostics test on proportional hazard assumptions first. The corresponding hazard ratio, 2- and 3-year EFS estimates will be assessed, and EFS medians along with their 95% confidence intervals for the two treatment arms. |
Time from induction response to the time of progressive-disease, secondary malignancy, or death, assessed up to 3 years
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease-free survival (DFS)
大体时间:Time from achievement of complete response (CR) to the time of relapse and/or death, assessed up to 10 years
|
Time from achievement of complete response (CR) to the time of relapse and/or death, assessed up to 10 years
|
|
|
Overall Survival (OS)
大体时间:Time from randomization to the time of death due to any cause, assessed up to 10 years
|
Will be evaluated using Kaplan-Meier as well as Cox regression models. |
Time from randomization to the time of death due to any cause, assessed up to 10 years
|
|
Proportion of patients who achieve CR or any response to induction therapy
大体时间:Up to 10 years
|
Will be summarized as the proportion of patients who achieve any type of response to induction therapy divided by the number of all evaluable patients registered to this trial and who received at least one dose of induction therapy. Corresponding 95% binomial confidence intervals will also be calculated. |
Up to 10 years
|
|
Overall induction response rates
大体时间:Up to 10 years
|
Will be summarized as the proportion of patients who achieve any type of response to induction therapy divided by the number of all evaluable patients registered to this trial and who received at least one dose of induction therapy. Corresponding 95% binomial confidence intervals will also be calculated. |
Up to 10 years
|
|
Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0
大体时间:Up to 10 years
|
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. In addition, all adverse event data that is graded as 3, 4, or 5 will be reviewed and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The incidence of severe (grade 3+) adverse events or toxicities will be described for each treatment arm, but will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest between the treatment arms and we will graphically assess differences in maximum grades observed for toxicities between the arms. Tolerability of the treatment arms will be assessed through assessing the number of patients who required dose modifications and/or dose delays. |
Up to 10 years
|
|
Proportion of patients who go off treatment due to adverse reactions
大体时间:Up to 10 years
|
Will be assessed within each of the treatment arms and differences explores in these measures between the arms. |
Up to 10 years
|
|
Proportion of patients who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial
大体时间:Up to 10 years
|
Will be assessed within each of the treatment arms and differences explores in these measures between the arms. |
Up to 10 years
|
合作者和调查者
调查人员
调查人员
- 学习椅:daniel_deangelo@dfci.harvard.edu J. DeAngelo, MD, PhD、Dana-Farber Cancer Institute
出版物和有用的链接
一般刊物
- Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 肿瘤
- 免疫系统疾病
- 感染
- 病毒病
- 组织学类型的肿瘤
- DNA 病毒感染
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 淋巴瘤,非霍奇金
- 淋巴瘤,B细胞
- 淋巴瘤
- 爱泼斯坦-巴尔病毒感染
- 疱疹病毒科感染
- 肿瘤病毒感染
- 半身和淋巴疾病
- 伯基特淋巴瘤
- 氨基酸,肽和蛋白质
- 蛋白质
- 硫化合物
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 调查技术
- 标本处理
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 手术程序,手术
- 细胞学技术
- 核酸,核苷酸和核苷
- 细胞诊断
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 生物碱
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 吲哚
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 嘌呤
- 胞苷
- 嘧啶核苷
- 嘧啶
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 类固醇,氟化
- 诊断技术,手术
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 核苷
- 翼
- 翼状
- 疗法
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 阿拉伯核苷
- 氨基翅目
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 抗体,单克隆,鼠的衍生
- 亚硫烯基化合物
- Calicheamicins
- 利妥昔单抗
- 伊珠单抗奥佐米星
- 地塞米松
- 甲氨蝶呤
- 环磷酰胺
- 阿糖胞苷
- 阿霉素
- 长春新碱
- 柔红霉素
- 巯基嘌呤
- 硫鸟嘌呤
- 别嘌呤醇
- 活检
- pegaspargase
其他研究编号
其他研究编号
- A041501
- U10CA180821 (美国 NIH 拨款/合同)
- NCI-2016-01981 (注册表标识符:Clinical Trial Reporting Program)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.